Get started
Author

Jaanki Khandelwal

Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma
2025 · Mohammad Jad Moussa, Jaanki Khandelwal, et al. · Journal for ImmunoTherapy of Cancer · 12
PDF
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract
2023 · Omar Alhalabi, Nathaniel Wilson, et al. · European Urology Oncology · 10
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy
2024 · Mohammad Jad Moussa, Jaanki Khandelwal, et al. · Current Oncology · 8
Clinical efficacy of lurbinectedin in metastatic neuroendocrine carcinomas of the genitourinary tract: Multi-institutional real-world experience.
2024 · Mohammad Jad Moussa, Syed Arsalan Ahmed Naqvi, et al. · Journal of Clinical Oncology · 8
Efficacy and safety of nivolumab plus ipilimumab (Nivo/Ipi) in patients with metastatic variant histology renal cell carcinoma.
2025 · Mohammad Jad Moussa, Jaanki Khandelwal, et al. · Journal of Clinical Oncology · 1
PDF
523 Nivolumab and ipilimumab in patients with metastatic non-clear cell renal cell carcinoma at MD Anderson Cancer Center
2023 · Jaanki Khandelwal, Devaki S Surasi, et al. · Regular and Young Investigator Award Abstracts
PDF
Characteristics and outcomes for patients (pts) with metastatic small cell urothelial carcinoma (mSCUC).
2023 · Nathaniel R. Wilson, Jaanki Khandelwal, et al. · Journal of Clinical Oncology
Works count: 7
Citation count: 39
H-index: 4
I10-index: 2
Year
Topic
Type